Related Experiment Video

Updated: Jul 20, 2026

In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Angiogenesis for the treatment of inoperable coronary disease: the future

Frank W Sellke1, Roger Laham, Erik J Suuronen

  • 1Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. fsellke@bidmc.harvard.edu

Seminars in Cardiothoracic and Vascular Anesthesia
|September 9, 2006
PubMed

Insights

Therapeutic angiogenesis aims to restore blood flow in severe coronary artery disease when traditional treatments fail. While promising, this approach requires further development to achieve significant clinical benefits.

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Vascular Biology

Background:

  • Severe coronary artery disease (CAD) presents challenges even with advanced treatments like angioplasty and bypass surgery.
  • Diffuse and severe CAD can limit the effectiveness of conventional interventions in restoring myocardial blood flow.
  • Existing therapies may not adequately address complex cases of chronic ischemia.

Purpose of the Study:

  • To explore therapeutic angiogenesis as a strategy to restore perfusion in chronically ischemic myocardium.
  • To investigate protein growth factors, gene therapy, and cell-based therapy for treating refractory CAD.
  • To overcome limitations of current treatments for severe coronary artery disease.

Main Methods:

  • Utilizing protein growth factors to stimulate new blood vessel formation.
  • Employing gene therapy to promote vascularization in ischemic heart tissue.
  • Investigating cell-based therapies as a novel approach for therapeutic angiogenesis.
  • Focusing on non-invasive strategies that bypass epicardial coronary arteries.

Main Results:

  • Therapeutic angiogenesis has not yet demonstrated significant clinical benefit for CAD patients.
  • Current angiogenesis approaches are experimental and reserved for patients unresponsive to standard therapies.
  • The potential of endogenous inhibitors of vascular development remains an area for future research.

Conclusions:

  • Therapeutic angiogenesis holds future promise for treating coronary artery disease by mimicking natural vascularization processes.
  • Modifying endogenous inhibitors of vascular development could enhance the efficacy of angiogenesis.
  • Further research is needed to translate the potential of therapeutic angiogenesis into a major clinical modality for CAD treatment.

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease08:38

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...